# Glyscend

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glyscend

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.glyscend.com
- Total disclosed funding: $21M
- Latest round: Series A (Jun 11, 2020)
- Investors on record: 3

## About

Glyscend, Inc. develops innovative oral therapeutic solutions that target type 2 diabetes and obesity, providing non-invasive alternatives to traditional bariatric procedures for effective weight management and glycemic control.Founded in 2014, Glyscend, Inc. is based in Baltimore, US, specializing in solutions for type 2 diabetes and obesity. The company was co-founded by Ashish Nimgaonkar and Thomas Jozefiak. It has successfully raised USD 20.5 mn in Series A funding co-led by Brandon Capital Partners and Santé Ventures on June 11, 2020. Glyscend has completed three funding deals to date.Glyscend, Inc. specializes in developing innovative therapeutic solutions aimed at treating type 2 diabetes and managing weight for overweight and obese patients. The company's core product offerings are based on a polymer therapeutic platform designed to mimic the physiological effects of bariatric surgery without the need for invasive procedures. These orally administered drugs aim to replicate the benefits of gastric bypass surgery and duodenal exclusion devices, helping to manage glucose levels and support weight loss in patients. Glyscend targets various geographical markets, including the United States and potentially other regions with a significant population of individuals affected by type 2 diabetes and obesity. The end-users of Glyscend’s products primarily include patients suffering from these conditions, alongside healthcare providers who facilitate their treatment.Glyscend's revenue model revolves around partnerships and collaborations with healthcare providers and pharmaceutical distribution channels. The company engages in B2B transactions, supplying its oral therapeutic products to healthcare systems and institutions that cater to diabetes and obesity management. The structured transactions involve direct sales agreements or collaborative arrangements with healthcare organizations, ensuring the products reach the end-users effectively. Key offerings include their trademarked products designed to non-invasively aid in weight management and glycemic control, reinforcing the company's commitment to enhancing patient outcomes.Following its recent Series A funding of USD 20.5 mn in June 2020, Glyscend, Inc. plans to advance the development of its therapeutic solutions. The company aims to expand its market presence, focusing on the United States and evaluating opportunities in additional regions with high diabetic and obese populations. The funding will support their efforts to enhance product development and increase distribution capabilities to effectively meet the healthcare needs of these markets.

## Funding rounds

- Series A, Jun 11, 2020, $21M — Brandon Capital Partners, Sante Ventures
- Seed, Jun 30, 2019 — Breakout Ventures

## Investors

- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Seed
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series A
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A